» Articles » PMID: 29379163

C-Src Activity is Differentially Required by Cancer Cell Motility Modes

Overview
Journal Oncogene
Date 2018 Jan 31
PMID 29379163
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Cancer cell migration requires that cells respond and adapt to their surroundings. In the absence of extracellular matrix cues, cancer cells will undergo a mesenchymal to ameboid transition, whereas a highly confining space will trigger a switch to "leader bleb-based" migration. To identify oncogenic signaling pathways mediating these transitions, we undertook a targeted screen using clinically useful inhibitors. Elevated Src activity was found to change actin and focal adhesion dynamics, whereas inhibiting Src triggered focal adhesion disassembly and blebbing. On non-adherent substrates and in collagen matrices, amoeboid-like, blebbing cells having high Src activity formed protrusions of the plasma membrane. To evaluate the role of Src in confined cells, we use a novel approach that places cells under a slab of polydimethylsiloxane (PDMS), which is held at a defined height. Using this method, we find that leader bleb-based migration is resistant to Src inhibition. High Src activity was found to markedly change the architecture of cortical actomyosin, reduce cell mechanical properties, and the percentage of cells that undergo leader bleb-based migration. Thus, Src is a signal transducer that can potently influence transitions between migration modes with implications for the rational development of metastasis inhibitors.

Citing Articles

Nucleating amoeboid cancer cell motility with Diaphanous related formins.

Kar N, Logue J Cytoskeleton (Hoboken). 2024; 82(3):91-97.

PMID: 38761126 PMC: 11570701. DOI: 10.1002/cm.21880.


Mechanical properties of human tumour tissues and their implications for cancer development.

Massey A, Stewart J, Smith C, Parvini C, McCormick M, Do K Nat Rev Phys. 2024; 6(4):269-282.

PMID: 38706694 PMC: 11066734. DOI: 10.1038/s42254-024-00707-2.


The amoeboid migration of monocytes in confining channels requires the local remodeling of the cortical actin cytoskeleton by cofilin-1.

Ullo M, DAmico A, Lavenus S, Logue J Sci Rep. 2024; 14(1):10241.

PMID: 38702365 PMC: 11068741. DOI: 10.1038/s41598-024-60971-1.


Development of a stemness-related prognostic index to provide therapeutic strategies for bladder cancer.

Fu S, Tan Z, Shi H, Chen J, Zhang Y, Guo C NPJ Precis Oncol. 2024; 8(1):14.

PMID: 38245587 PMC: 10799910. DOI: 10.1038/s41698-024-00510-3.


Dasatinib suppresses collective cell migration through the coordination of focal adhesion and -cadherin in colon cancer cells.

Lu Y, Hou X, Koo H, Chao W Heliyon. 2024; 10(1):e23501.

PMID: 38187289 PMC: 10770570. DOI: 10.1016/j.heliyon.2023.e23501.


References
1.
MacKay H, Au H, McWhirter E, Alcindor T, Jarvi A, MacAlpine K . A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium. Invest New Drugs. 2011; 30(3):1158-63. DOI: 10.1007/s10637-011-9650-4. View

2.
Sahai E, Marshall C . Differing modes of tumour cell invasion have distinct requirements for Rho/ROCK signalling and extracellular proteolysis. Nat Cell Biol. 2003; 5(8):711-9. DOI: 10.1038/ncb1019. View

3.
Mayer E, Baurain J, Sparano J, Strauss L, Campone M, Fumoleau P . A phase 2 trial of dasatinib in patients with advanced HER2-positive and/or hormone receptor-positive breast cancer. Clin Cancer Res. 2011; 17(21):6897-904. DOI: 10.1158/1078-0432.CCR-11-0070. View

4.
Case L, Waterman C . Integration of actin dynamics and cell adhesion by a three-dimensional, mechanosensitive molecular clutch. Nat Cell Biol. 2015; 17(8):955-63. PMC: 6300998. DOI: 10.1038/ncb3191. View

5.
Kluger H, Dudek A, McCann C, Ritacco J, Southard N, Jilaveanu L . A phase 2 trial of dasatinib in advanced melanoma. Cancer. 2011; 117(10):2202-8. PMC: 3116034. DOI: 10.1002/cncr.25766. View